Metabolic Syndrome Effects on Bone Health

Metabolic syndrome, characterised by central obesity, insulin resistance, dyslipidaemia and hypertension, exerts a multifaceted influence on skeletal integrity. The interplay between excess adiposity and bone remodelling processes can lead to alterations in bone mineral density and microarchitecture, with divergent outcomes according to age, sex and body composition. Chronic low-grade inflammation driven by adipose-derived cytokines and impaired insulin signalling may disrupt osteoblast and osteoclast activity, shifting the balance towards bone loss in susceptible individuals. Conversely, the mechanical loading associated with higher body mass index can confer a protective effect on bone mass, creating a complex clinical picture. Epidemiological studies have reported inconsistent associations between metabolic syndrome and risk of osteoporosis or fracture, reflecting variable definitions of syndrome components, population heterogeneity and differing assessment methods. Given the rising prevalence of metabolic syndrome worldwide and the ageing of populations, understanding its skeletal repercussions is crucial for developing integrated strategies to preserve bone health and reduce fracture burden.

Research from Nature Portfolio

Recent work in a large East Asian cohort employed quantitative ultrasound to assess bone density in adults aged 30–50 years. Findings indicated that metabolic syndrome was linked to increased risk of low bone density, particularly among individuals with lower body mass index, and that lifestyle factors such as smoking, excess alcohol intake and physical inactivity further exacerbated skeletal vulnerability. This study underscores the importance of a holistic approach, combining weight management with behavioural interventions to mitigate bone loss.

A foundational review in a leading endocrinology series has distilled molecular insights into how adipokines, inflammatory mediators and altered hormonal signals converge on bone tissue. Key pathways include regulation of calcium homeostasis, modulation of the receptor activator of nuclear factor-κB ligand–osteoprotegerin axis and perturbation of Wnt–β-catenin signalling, which together orchestrate osteoblast differentiation and osteoclast activity. These mechanistic frameworks offer potential therapeutic targets to counteract the skeletal effects of metabolic dysregulation.

Metabolic Syndrome Effects on Bone Health publication trend

The graph below shows the total number of articles in metabolic syndrome effects on bone health across all publications each year (not limited to Nature Index journals).

Technical terms

Metabolic syndrome: A cluster of interconnected risk factors including central obesity, insulin resistance, dyslipidaemia and hypertension that increases the likelihood of cardiovascular disease and type 2 diabetes.

Bone mineral density (BMD): A quantitative measure of mineral content within bone tissue, usually assessed by dual-energy X-ray absorptiometry or quantitative ultrasound, reflecting bone strength.

Osteoporosis: A skeletal disorder characterised by reduced bone mass and microarchitectural deterioration, leading to increased fracture susceptibility.

Adipokine: A bioactive peptide secreted by adipose tissue that can modulate inflammation, metabolism and bone remodelling.

Trabecular bone: The spongy, porous inner structure of bone that provides flexibility and supports load distribution, particularly sensitive to metabolic changes.

References

1. Linking metabolic syndrome with low bone mass through insights from BMI and health behaviors. Scientific Reports (2023).
2. The Impact of Metabolic Syndrome on Bone Mass in Men: Systematic Review and Meta-Analysis. Biomedicines (2023).
3. The Relationship between Metabolic Syndrome and Osteoporosis: A Review. Nutrients (2016).
4. Metabolic Syndrome in Arab Adults with Low Bone Mineral Density. Nutrients (2019).